- Home
- RFI vs MGTX Comparison
RFI vs MGTX Comparison
Compare RFI & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | MGTX |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 294.2M | 744.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RFI | MGTX |
|---|---|---|
| Price | $10.96 | $8.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.83 |
| AVG Volume (30 Days) | 69.8K | ★ 625.1K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,417,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 96.83 |
| 52 Week Low | $9.62 | $4.55 |
| 52 Week High | $12.52 | $9.73 |
Technical Indicators
Market Signals| Indicator | RFI | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.43 | 59.23 |
| Support Level | $11.06 | $8.25 |
| Resistance Level | $11.46 | $9.50 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 11.16 | 67.86 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.